首页 | 官方网站   微博 | 高级检索  
     


Indolo‐Phakellins as β5‐Specific Noncovalent Proteasome Inhibitors
Authors:Dr Philipp Beck  Theresa A Lansdell  Nicole M Hewlett  Prof?Dr Jetze J Tepe  Prof?Dr Michael Groll
Affiliation:1. Center for Integrated Protein Science Munich (CIPSM), Department für Chemie, Technische Universit?t München, Lichtenbergstrasse 4, 85748 Garching (Germany);2. Department of Chemistry, Michigan State University, East Lansing, Michigan 48823 (USA)
Abstract:The proteasome represents an invaluable target for the treatment of cancer and autoimmune disorders. The application of proteasome inhibitors, however, remains limited to blood cancers because their reactive headgroups and peptidic scaffolds convey unfavorable pharmacodynamic properties. Thus, the discovery of more drug‐like lead structures is indispensable. In this study, we present the first structure of the proteasome in complex with an indolo‐phakellin that exhibits a unique noncovalent binding mode unparalleled by all hitherto reported inhibitors. The natural product inspired pentacyclic alkaloid binds solely and specificially into the spacious S3 subpocket of the proteasomal β5 substrate binding channel, gaining major stabilization through halogen bonding with the protein backbone. The presented compound provides an ideal scaffold for the structure‐based design of subunit‐specific nonpeptidic proteasome‐blockers.
Keywords:alkaloids  drug discovery  halogen bonding  natural products  reversible inhibition
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号